News

Appointments add scientific, clinical, and business depth as three Phase 1 intravenously-dosed oncolytic viral programs advance in the clinic

SAN DIEGO — Oct. 1, 2026 — ViroMissile, Inc., a cancer immunotherapy company pioneering the IDOV™ (Intravenously Deliverable Oncolytic Virus) platform, today announced the completion of the first dose cohort…

IDOV-Safe demonstrates efficient intravenous delivery, manageable safety, and encouraging anti-tumor activity in heavily pretreated patients with pMMR/MSS metastatic colorectal cancer, supporting further evaluation in a Phase 2 study SAN DIEGO…

Study examines the safety and early efficacy of an oncolytic virus via a single intravenous dose SAN DIEGO — February 17, 2026 — ViroMissile, Inc., a cancer immunotherapy company pioneering…

SAN DIEGO — January 21, 2026 — ViroMissile, Inc., a cancer immunotherapy company pioneering the IDOV™ (Intravenously Deliverable Oncolytic Virus) platform, today announced the appointment of Michael G. Wood as…

Study examines the safety and early efficacy of an oncolytic virus via a single intravenous dose SAN DIEGO — December 11, 2025 — ViroMissile, Inc., a cancer immunotherapy company pioneering…

SAN DIEGO — December 4, 2025 — ViroMissile, Inc., a cancer immunotherapy company pioneering the IDOVTM (Intravenously Deliverable Oncolytic Virus) platform, today announced the appointment of Mark Bertagnolli as Chief…

SAN DIEGO -- ViroMissile was recognized by "Life Sciences Review" magazine as the Top Cancer Destroying Platform 2025. A pioneering biotech firm headquartered in San Diego, ViroMissile is transforming the landscape of…